French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Tuesday that it has received US Food and Drug Administration (FDA) 510(k) clearance for its VITEK COMPACT PRO system.

The new system enhances microorganism identification (ID) and antibiotic susceptibility testing (AST), supporting clinical laboratories in diagnosing infectious diseases and addressing antimicrobial resistance.

VITEK COMPACT PRO builds on the strengths of its predecessor, VITEK 2 COMPACT, offering an advanced design and a more efficient workflow. It provides faster routine ID/AST results, allowing clinicians to optimise patient care while improving laboratory efficiency. The system is ideal for small and medium-sized laboratories and facilitates the transition from manual workflows to automated processes, bioMérieux said.

For industrial applications, VITEK COMPACT PRO will identify pathogens to ensure the safety of food, pharmaceutical and cosmetic products. Commercial launch is planned in selected countries, with a global rollout expected in the second quarter of 2025.